Drug safety guidance
This article was originally published in The Tan Sheet
FDA has abandoned its original idea for a Drug Watch Web site and will instead post drug safety information on a Drug-Specific Information Web site on the Center for Drug Evaluation and Research home page, the agency announces in a final guidance released March 2. Drug sponsors will be notified that emerging drug safety data will be posted at least 24 hours before the information is communicated, the agency adds. The guidance, which outlines how FDA plans to communicate drug safety information to the public, follows a May 2005 draft guidance, which proposed having Drug Watch list drugs considered as having significant emerging safety risks. However, many comments received by the agency stated that such a name might create confusion with the current MedWatch program. The Consumer Healthcare Products Association stated in its own comments on Drug Watch that information should be posted only after its significance had been "fully determined" (1"The Tan Sheet" Aug. 15, 2005, p. 3)...
You may also be interested in...
FDA should include drug safety information on its new Drug Watch system only after a review has "fully determined the significance of the information, causal or otherwise," according to the Consumer Healthcare Products Association
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.